Moderna has entered into a significant collaboration with OpenAI to integrate artificial intelligence across its operations. This partnership, as reported by multiple sources including the Wall Street Journal, aims to transform Moderna's approach to biotechnology by automating nearly every business process and enhancing the productivity of its workforce. Sam Altman, OpenAI's CEO, stated that AI will increasingly perform more science, aiming to enhance productivity and accelerate capabilities. The collaboration, which began in early 2023, includes the deployment of Moderna's own version of ChatGPT, named mChat, achieving over 80% internal adoption. Moderna has also created over 400 GPTs for research tasks. The companies plan to develop 15 new products over the next five years, focusing on life-saving vaccines and individualized cancer treatments. OpenAI provides dedicated support to Moderna, including weekly strategy calls and a shared communication channel for quick problem-solving.